Ash Access Technology, Inc. Investigational Antimicrobial / Antithrombotic Therapy (Zuragen(TM)) Pivotal Clinical Trial Begins
Published: Oct 03, 2006
LAFAYETTE, IN -- (MARKET WIRE) -- October 02, 2006 -- Ash Access Technology, Inc., a privately held specialty pharmaceutical and medical device company, announced that patient enrollment had been initiated this August for the pivotal clinical trial of its flagship antimicrobial / antithrombotic therapy, Zuragen™. The clinical trial is a multi-centered study evaluating the efficacy and safety of Zuragen™ for the prevention of catheter related bloodstream infection (CRBSI) in dialysis patients. The trial will enroll 400 patients and consist of 10 study sites, eight of which are associated with DaVita Inc., and two independent clinics in Bakersfield, CA, and Lafayette, IN. The company will finance a portion of the trial through an SBIR Phase I & II NIH grant awarded in 2005 and a grant from the Indiana 21st Century Technology Fund received this year.